Oruka Therapeutics, Inc. Proceeds from (Payments for) Other Financing Activities
Oruka Therapeutics, Inc. (ORKA) reported Proceeds from (Payments for) Other Financing Activities of $227.95 million for the 11-month period ending 2024-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromPaymentsForOtherFinancingActivities · last filed 2026-03-12
- 2024-12-31: Proceeds from (Payments for) Other Financing Activities 11 month $227.95M.
- 2024-09-30: Proceeds from (Payments for) Other Financing Activities 8 month $228.13M.
| Period end | Proceeds from (Payments for) Other Financing Activities 8 month | Proceeds from (Payments for) Other Financing Activities 11 month |
|---|---|---|
| 2024-12-31 | $227.95M 10-K · filed 2026-03-12 | |
| 2024-09-30 | $228.13M 10-Q · filed 2025-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |